
Opinion|Videos|June 9, 2025
The MOA of TLX250
Panelists discuss how the new tracing agent (Zr-DFO-girentuximab or 2050) works by binding to carbonic anhydrase IX, an enzyme expressed on the surface of most clear cell renal cancers, coupled with zirconium for radiographic detection.
Advertisement
Episodes in this series

The Novel Tracer 89Zr-TLX250
Main Discussion Topics:
- 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX).
- CAIX is an enzyme expressed on the surface of most clear cell renal cell carcinomas (ccRCCs).
- The antibody is coupled to zirconium-89, a positron emitter detectable on PET imaging.
Key Points for Physicians:
- The tracer targets CAIX, which is highly expressed in ccRCC.
- The mechanism of action involves antibody binding coupled with a radioactive tracer.
- Zirconium-89 serves as the positron-emitting component for detection.
Notable Insights:
The targeting of CAIX represents a specific molecular approach to identifying ccRCC based on its unique expression pattern.
Clinical Significance:
This targeted molecular approach represents a fundamental shift from anatomic to biological characterization of renal masses.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
FDA updates in urology: May 2026
5











